1,165 Views
Preconference Workshop
Applied
Andrea Laslop, MD
Head of Scientific Office, Austrian Medicines and Medical Devices Agency
Matthias Dormeyer, Dr
Managing Director
Sabine Haubenreisser, MSc, PhD
Principal Scientific Administrator
European Medicines Agency
Karl-Heinz Huemer, MD, PhD
Medical Assessor
AGES (Austrian Agency for Health & Food Safety)
Bjorn Oddvar Strom, MPharm, PdD
Senior Scientific Advisor
Norwegian Medicines Agency
Maria Concepcion Yerro, MD, PhD
Spanish Agency for Medicines and Medical Devices
Pharmaceutical companies intending to develop and register drugs for the European market need to be aware that the regulatory network in the EU has its own requirements and characteristics which differ in a number of aspects from FDA. Knowledge of the general and distinctive features of the centralized regulatory system in the EU, as coordinated by EMA, with special focus also given on novel regulatory approaches, will benefit successful development and approval of drugs in Europe. Drug development is a multi-step approach that involves a number of opportunities and requirements for interaction with regulatory authorities, spanning from the design and approval of clinical trials, use of scientific advice and other support programs during development, definition of potential orphan status, and pediatric development to specific aspects of advanced therapy products and ways of approval and post-marketing activities/commitments. This workshop will address the various regulatory steps and explain the role of the European regulator not only as being a gate-keeper but also an enabler supporting successful development. Established and new approaches, as provided by the European regulatory network, will be presented and discussed on the basis of anonymized examples and on discussion of practical cases/questions contributed by workshop attendees.